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Abstract 
 
Background: Anti- muscle specific kinase antibody positive (MuSK Ab) myasthenia gravis (MG) 
patients are known to have different clinical course compared to acetylcholine receptor Ab 
positive MG patients.  Therapeutic plasma exchange (TPE) has been reported to be effective; 
however, little is known of the response and of TPE procedural information.  An ASFA 
Apheresis Registry was developed to analyze those data.  Methods: The study collected detailed 
de-identified patient data, TPE procedures, and treatment outcome/complications. Collected data 
was described in aggregate.  Results: A total of 15 MuSK Ab MG patients with exacerbation of 
MG symptoms, 13 females/2 males, median age 44, were investigated. Thirty TPE courses 
(median 5 procedures/course, total 145 procedures) were evaluated.  All TPE procedures were 
performed with citrate anticoagulation, 1-1.25 plasma volume exchange in 100% fluid balance, 
and 90% of courses used only albumin as replacement.  Calcium was added to albumin or given 
orally as needed.  TPE was performed every other day in 55% of courses.  Adverse events 
occurred in 3.4% of procedures.  Ten patients (67%) experienced relapses within a median of 7 
weeks.  Objective symptoms were resolved in more than 75% of courses.  Overall subjective 
improvement rates were 94.1%/93.3% after 3/4 TPE procedures, respectively.  Thirty-one 
percent of patients responded poorly with minimal recovery.  Conclusion: Overall subjective 
improvement was seen up to 94% of patients after one course of TPE.  Some patients were poor-
responders.  Five TPE may be adequate for initial course with additional TPE as needed.  Based 
upon this preliminary data, we will modify our future data collection.   
Key Words: ASFA apheresis registry, Therapeutic plasma exchange, MuSK MG  
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Introduction 
 
Approximately 20% of Myasthenia gravis (MG) patients do not have acetylcholine 
receptor (AchR) antibodies (Abs) defining a conditions known as “sero-negative” MG. [1] 
However, additional auto-antibodies to other neuromuscular junction proteins have been recently 
discovered in these patients such as antibodies directed against muscle specific kinase (MuSK) 
[1], the muscle proteins titin or ryanodine [2], and lipoprotein receptor-related protein 4 (Lrp4) 
[3].  Other potential antigenic targets include neural agrin, which binds to Lrp4, and CoIQ which 
is a part of acetylcholinesterase complex [4].  
Anti-MuSK Ab positive MG (MuSK MG) patients are often reported to have a different 
clinical course compared to anti-AchR Ab positive MG (AchR MG) patients.  The repeatedly 
reported features of MuSK MG patients compared to AchR MG patients are listed in Table 1.  
Therapeutic plasma exchange (TPE) is reported to be one of the effective treatments for MuSK 
MG patients.  Maintenance TPE has also been reported to be beneficial, resulting in patients 
having little or no symptoms for protracted periods of time. [5]   However, little is known how 
the clinical response relates to the performance of TPE, including total number of procedures, 
frequency of the procedure, or replacement fluid during a course of treatment.   
The multi-institutional apheresis registry was developed by the American Society for 
Apheresis (ASFA) Research subcommittee.  The aim is to collect and analyze outcome, safety, 
and practice information related to apheresis.  We collected data from the patients with MuSK 
MG who received TPE treatment as a part of the apheresis registry and report the first data 
summary.  
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Materials and Methods 
 
The ASFA Apheresis Registry is a multi-institutional database which currently has data 
from 17 medical centers / facilities from across the United States.  For this first report for MuSK 
MG registry, New York-Presbyterian Hospital-Columbia University Medical Center (New York, 
NY), University of Michigan (Ann Arbor, MI), and Yale New Haven Hospital (New Haven, CT) 
identified MuSK MG patients and participated in data entry.  These facilities had obtained their 
Institutional Review Board (IRB) approval and a Data Usage Agreement to enter the detailed de-
identified patient demographic and clinical information, apheresis procedural information, 
treatment schedules, treatment outcome and procedural-complications into a Research Electronic 
Data Capture (REDCap) database, both retrospectively and prospectively.  The REDCap 
database is an electronic data capture tools hosted at Children’s National Medical Center and is a 
secure, web-based application designed to support data capture for research studies, providing 1) 
an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and 
export procedures; 3) automated export procedures for seamless data downloads to common 
statistical packages; and 4) procedures for importing data from external sources. [6]   
Included in the database were MG patients with anti-MuSK Ab who received a course of 
TPE due to symptomatic exacerbation.  Patients receiving TPE treatment at a frequency of less 
than one month were considered to be in a course of treatment.  If patients experienced a relapse 
and received another course of TPE treatment, the data for that course was entered separately.  
Although some patients received maintenance TPE between each course with more frequent TPE 
for symptomatic exacerbation, the data during the maintenance TPE was not collected.    
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The demographic data collected includes gender, race, age at diagnosis, and age at first 
TPE.  The TPE procedural data collected includes total number and frequency of procedures in 
one TPE course, plasma volume exchanged, type of replacement fluid, type of anticoagulant, 
type of access, use of RBC prime, the type of electrolyte (calcium, magnesium, and potassium) 
supplementation and adverse events.   
The clinical data collected includes symptoms, medications used, thymectomy, antibody 
specificity (AchR Ab and MuSK Ab), Edrophonium test results, electromyography (EMG) 
abnormalities, single fiber electromyography (SFEMG) abnormalities, and relapse.  Seven 
objective symptoms (diplopia, ptosis, dysarthria, dysphagia, limb weakness, shortness of breath 
[SOB], and intubation) were reported at onset of the disease, before and after each TPE, within 
one month, and 1-3 and 3-6 months after the last TPE when the data was available in the clinical 
record.  Since improvement was evaluated on subsequent patient encounter, the evaluation of the 
last TPE procedure in a course was not available.  The objective symptoms found in each 
patient’s clinical records at each time point retrieved by site study team member(s) at each 
facility were entered to the data base.  The subjective symptomatic improvement found in 
clinical records written by apheresis physicians or neurologists at each time point were retrieved 
and evaluated by site study team member(s) at each facility and categorized into no, mild, 
moderate, marked, and full improvement. Blood pressure (BP) before and after each TPE 
procedure was also recorded when available.  The medications (prednisone, hydrocortisone, 
methylprednisone, pyridostigmine, IVIG, rituximab, azathioprine, mycophenolate mofetil, and/or 
cyclosporine) before and after a course of TPE were also recorded when available.   
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Analysis for all collected data was performed in aggregate.  The descriptive analysis was 
mainly used with mean, median ratio and t-test when applicable.  For the t-test, a p-value of less 
than or equal to 0.05 was considered significant. 
 
Results 
 
Demographic data 
As of 9/1/15, a total of 15 MuSK Ab positive MG patients from 3 centers treated for 
exacerbation of MG symptoms between 2006 and 2013 had been entered into the registry.  
Thirteen patients were female (86.7%) and 2 patients were male (13.3%).  Seven patients were 
Caucasian, 2 patients were African American, 1 patient was Asian, and 5 patients were of 
unknown ethnicity.  The age at diagnosis was stratified by decade in life with 1, 3, 2, 4, 2 and 3 
patients in the 2
nd
, 3
rd
, 4
th
, 5
th
, 6
th
 and 7
th
 decade of life respectively.  Median age at diagnosis 
was 43 (14-66) years old, and median age at first TPE was 43 (16-67) years old.  
 
TPE procedures 
Summary of TPE procedural data is shown in Table 2 (occurrence rates are based on 
number of courses in Table 2A, based on number of procedures in Table 2B).  Thirty TPE 
courses (total of 145 procedures) were evaluated. All TPE procedures/courses used a 1-1.25 
plasma volume exchange with 100 % fluid balance and full rinse back. Anticoagulant citrate 
dextrose solution A (ACD-A) was used as the procedural anticoagulant.  The number of TPE 
procedures per course ranged from 2 to 10 procedures, with a median of 5 procedures overall.  
TPE frequency was reported in 29 courses; with TPE being performed most frequently every 
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other day in 16 of 29 (55.2%) courses.  The data for type of access was entered in 28 courses; 
peripheral veins were used in 14 of 28 (50.0%) courses and a central venous catheter was placed 
in 13 of 28 (43.3%) courses, primarily in the internal jugular vein.  Switching access from one 
type to another in one course was not reported.  Replacement fluid was 5% albumin only in 133 
of 145 (91.7%) procedures in 27 courses at all facilities and 5% albumin and normal saline in 12 
of 145 (8.3%) procedures in 3 courses with albumin: normal saline ratio of 5:1, 4:1, 5:2 and 1:1 
at one facility.  Calcium supplementation was reported in 136 procedures; calcium was added 
into albumin in 114 of 136 (83.8%) procedures in 25 courses at two facilities per protocol; and 
given orally in one of 136 (0.7%) procedures for citrate toxicity in one course.  None of the 
patients received potassium or magnesium supplementation and none required RBC priming.  
Adverse events were reported in 5 of 145 (3.4%) procedures.   
 
Clinical course 
One of the 15 patients also had anti-AchR Ab in addition to anti-MuSK Ab and 
underwent thymectomy.  A total of 3 patients (20%) underwent thymectomy.  Positive 
Edrophonium test was reported in 2 patients (13.3%), abnormal EMG and SFEMG were reported 
in 2 (13.3%) and 5 patients (33.3%) respectively.  Pre-procedure BP was reported in 127 
procedures, and post-procedure BP was reported in 23 procedures.  Pre-procedure 
systolic/diastolic pressure ranged 85-183/45-107 mmHg and 92-148/62-90 mmHg post-
procedure respectively.   
Table 3 shows percentage of objective symptoms at onset and immediately prior to each 
TPE course, and the full recovery percentage of each symptom after a course of TPE.  
Immediately prior to each TPE course (n=30), each symptom was reported to be present in more 
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than 40% of courses except intubation.    Within the patients who had each symptom before TPE 
treatment, the full recovery percentage of symptom was more than 75%.  
Subjective improvement was evaluated before each subsequent TPE; therefore, subjective 
findings were typically not available after the last TPE in one treatment course.  Because most 
patients received 5 TPE per course, subjective improvement by procedure is primarily limited to 
the first 4 procedures: two patients received more than 5 TPE.  Table 4 shows total number of 
TPE procedures in one course and final subjective improvement level in reported 25 TPE courses.  
None, mild, moderate, marked and full improvement were found in 3, 6, 5, 7, 4 courses 
respectively.  Table 5 shows the degree and percentage of improvement after each TPE 
procedure in up to 25 reported treatment courses.  Any degree (mild to full) of improvement was 
achieved in 94.1% and 93.3% with marked improvement of 29.4% and 40% after 3
rd
 and 4
th
 TPE 
procedure, respectively.  Of note, since the numbers of reported courses are different depending 
on 1
st
 to >5
th
 TPE, the occurrence percentage of improvement is based on the number of reported 
courses in each evaluation time.   
Pre-procedure medications in 30 courses are listed in Table 6.  Before the first TPE, 
patients were taking prednisone and pyridostigmine in more than 40 % of the courses.    None of 
the patients were receiving methylprednisone and cyclosporine, however, one patient received 
methylprednisone during the course of TPE most likely on admission to the hospital.  The dose 
of prednisone was reported in 14 courses after a course of TPE and 13 courses within 3 months 
(Table 7A).  The prednisone dose was not changed at either evaluation times in the majority of 
the treatment courses.    The dose of pyridostigmine was reported only in 6 and 5 courses after a 
course of TPE and within 3 months, respectively (Table 7B).  The pyridostigmine dose was 
decreased at both evaluation times in the majority of the treatment courses.    
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Ten patients (67%) experienced one or multiple relapses within a median of 7 weeks (2 
weeks – 18 months) after the last TPE in one course of treatment.   
 
Discussion 
 
MG is an autoimmune disease and relatively common condition.  Treatment regimens 
such as steroids, immunosuppressives, cholinesterase inhibitors, thymectomy,  IVIG and TPE, 
have decreased mortality rate from MG substantially.  However, some patients with “sero-
negative” MG still experience severe symptoms.  Many patients with “sero-negative” MG have 
anti-MuSK bs and have been reported to respond well to TPE. [7-11]  However; details of TPE 
procedure and patient clinical responses have not been investigated.   
Our emographic data showed female predominance, which is the same as already 
published reports of MuSK MG patients.  However, the highest occurrence age in our study was 
in the 5
th
 decade of life, which is slightly older than those found in previous reports (3
rd
 and 4
th
 
decade of life) [7-11].  This may be due to the limited number of patients in our study.  The 
clinical feature of MuSK MG patients in our study confirmed reported features including low 
incidence of thymectomy and abnormal EMG, high incidence of more severe symptoms, 
oculobulbar symptoms, relapse and abnormal SFEMG. [7-11]  We included one patient who had 
both anti-AchR Ab and anti-MuSK Ab from our analysis at this time because we could not 
exclude the symptoms from anti-AchR Ab and because of limited number of participants.  We 
consider separating those patients in future data analysis.      
  In our study, we found that five TPE procedures were performed as a course of treatment 
in 14 of 30 (46.7%) courses.  We surmise this is mainly because 5 procedures in one TPE course 
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are necessary to assess a patient’s initial response to TPE for many neurological diseases in some 
facilities.  This may be based on ASFA’s recommendation to typically performed 5-6 procedures 
for any disease (with few exceptions) and because of institutional protocol.  In our study, TPE 
was performed every other day in 55.2% of courses; however, we did not stratify TPE frequency 
based on the severity of symptoms.  Further study may be necessary to determine if changes in 
procedural frequency ameliorate certain symptoms faster than others.  Overall, plasma volumes 
exchanged (1-1.25 of plasma volume), 100% fluid balance, full rinse back, calcium 
supplementation and anticoagulation (ACD-A) use were the predominant TPE procedural 
features in the facilities surveyed.  RBC prime for the procedure was not performed in any 
procedure most likely because all participated patients were adults.  
Albumin (5%) was used as a replacement fluid in the majority of procedures, with 12 
procedures in 3 courses using combination of 5% albumin and normal saline in variable ratio 
with 100% fluid balance.  All 3 courses were performed in one facility and the use of normal 
saline is most likely dependent on that facility’s TPE protocol.  Since normal saline has only a 
transient intravascular effect and can cause fluid and protein depletion [12] possibly leading to 
hypotension, some facilities avoid using normal saline other than priming of the apheresis 
machine.  The post-procedure BP showed variable change compared to pre-procedure BP in 
those 12 procedures without any clinical symptoms associated with BP; the systolic BP change 
ranged from -26 to +20 mmHg, the diastolic BP change ranged from -25 to +13 mmHg.  These 
changes may be significant depending on the patient’s condition, therefore, careful observation 
may be required.  However, in 10 procedures in 2 other courses which used only albumin in the 
same facility, systolic BP change ranged from -9 to +9 mmHg, and diastolic BP change ranged 
from -10 to +42 mmHg (from pre-TPE diastolic BP of 45 mmHg).  The difference of BP change 
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between with and without normal saline use is not statistically significant (systolic pressure 
change p=0.8364, diastolic pressure change p=0.1357).   
Incidence of adverse events with TPE varies in the literature between 1.6% and 25%. [13]  
Couriel reported overall TPE complication rate of 17% [14], while Mokrzycki reported a 
complication rate of 9.7% [15].  Mokrzycki also reported that hypocalcemia due to citrate was 
reduced to 1% with calcium prophylaxis from 9.1% without prophylaxis.  Our study 
demonstrated an incidence of adverse events of 3.4%.  Two adverse events were citrate toxicity.  
Calcium supplementation was not given for those two procedures, although it was given orally to 
treat the symptoms in one procedure.  Therefore, citrate toxicity occurred in 2 of 22 procedures 
(9.1%) with no calcium supplementation, and 0% with calcium supplementation, similar to the 
effect of calcium supplementation on hypocalcemia reported by Mokrzycki.  Thus, our study 
suggests that calcium supplementation may be needed to mitigate citrate toxicity while 
performing TPE procedures for MuSK Ab positive MG patients.  
In regards to response to TPE, more than 75% of any objective symptoms fully resolved 
after a course of TPE (Table 3).  Overall subjective improvement was also achieved up to 94.1% 
of courses (Table 5).  The most frequent mild, moderate, marked, and full improvement was 
found after 2
nd
, 3
rd
, 4
th
 and 4
th
 TPE procedures, respectively.  This observation represents 
increasing patient symptomatic improvement with increasing number of TPE procedures.  Given 
that patients did not make clinic visits soon after the 5
th
 procedure, we were not able to assess 
improvement in patient symptomatology after the 5
th
 procedure.  However, due to satisfactory 
improvement rate after the 4
th
 procedure, we surmise that 5 TPE procedures may be an 
appropriate initial number of TPE procedures in one course and further procedures can be added 
if the patients’ response is poor.   
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Four of reported 13 (30.8%) patients had only mild or no subjective improvement after 
one or two courses of TPE (Patients 1, 3, 14, 15, Table 4).  These patients received one or two 
courses of TPE treatments.  These patients may be poor- or non-responders to TPE.  Two other 
patients received more than 5 TPE procedures in 2 of 6 courses (Patient 7) and all 4 courses 
(Patients 13), probably for poor clinical response.  In these 2 patients, the response to TPE 
progressively diminished over time.  These patients initially had marked improvement after their 
first course but had mild or no improvement after their last treatment course.  Therefore, patients 
may be classified into 3 groups based on their response to TPE; 1. Patients with good sustainable 
response, 2. Patients with poor response, 3. Patients with diminishing response (initial good 
improvement, but not sustainable).  When the patients are classified in these three groups in our 
study, the prevalence was 53.8, 30.8, and 15.4% in group 1, 2, and 3, respectively.  However, 
additional patients are needed to confirm this observation.  
Although the use of maintenance TPE for MuSK MG patients was reported previously 
[5], the purpose of this study was to evaluate the response to TPE in patients with symptomatic 
exacerbation; therefore, we did not collect data for maintenance TPE.  The patient’s symptoms 
can be stabilized with maintenance TPE; however, mild to moderate relapses are not uncommon 
even during the maintenance TPE in those patients with anti-MuSK MG.  
Only limited number of information for medication dose was entered into REDCap 
system.  However, based on this limited data, TPE may have a potential to decrease prednisone 
within 3 months and pyridostigmine after a course of TPE.  Reducing high dose steroid is 
important in order to avoid side effects associated with its long-term use.  The additional entry of 
more MuSK MG patients may allow a more detailed analysis of medication reduction after a 
TPE course.   
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Our study had several limitations.  This included the low number of patients (n=15) and 
participating institutions (n=3), with one facility responsible for a large proportion of patients (10 
patients in one facility in 15 patients) and treatment courses (24 courses in one facility in 30 
courses) available for analysis.  As a result, TPE-specific parameters may be biased as to the 
number of procedures performed per TPE course or fluids and electrolyte replacement for each 
procedure.  No significant difference in symptoms, procedures, and response to TPE was 
observed between patients with (n=10) and without (n=5) relapses except an average age of 
onset; 49.2 years old in patients with relapses vs. 27.8 years old in patients without relapses 
(p=0.0098).  However, this result may be also due to limited number of patients.  The difference 
between responders and non-responders to TPE was also not justified due to limited number of 
patients at this point.  Therefore, our observations may change in the future, as data from more 
patients and facilities become available.       
Based on these results, we are considering modification of our methods to collect more 
clinically useful and statistically meaningful data.  In this regard, we are considering new 
methodology in standardizing and validating outcome measurements, which would allow 
confirmation of patient classification by response to TPE.  We are also planning to investigate 
unique clinical features of MuSK MG patients, to identify potential risk factors in patient with 
multiple relapses, to identify impact of TPE on medication doses, and to identify the impact of 
TPE in long term management such as maintenance TPE.   
In summary, this is the first multi-center registry study to evaluate demographic, TPE 
procedural and clinical data in MuSK MG patients who received TPE treatments. The overall 
subjective improvement was up to 94% after 4 TPE procedures; therefore, 5 TPE may be 
adequate as an initial course of TPE treatment for symptomatic exacerbation.  However, 30.8% 
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of the patients were poor- or non-responders to TPE and 15.4% of the patients experienced 
diminished response over the time.  We are considering modification of our methods to collect 
more practically useful and statistically meaningful data in the future based on our current data.  
Additional data from additional facilities will provide more accurate information in the context 
of the performance of TPE for this rare form of MG in the future.   
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Table 1: Reported features of MuSK MG patients [1, 5, 8, 9, 10, 11] 
 
1. Demographics 
a. Predominantly female 
b. Onset of symptoms in 4
th
 decade of life 
2. Clinical course 
a. More severe or refractory clinical symptoms 
b. More rapidly progressive course with increased risk of myastenic crisis 
3. Diagnostics 
a. Lower diagnostic yield in repetitive nerve stimulation (RNS) 
b. Myopathy-like electromyography (EMG) 
c. Frequent abnormal single-fiber electromyography (SFEMG) 
d. Normal thymus gland pathology 
4. Treatment response 
a. Poor response, more nicotinic and muscarinic side effects to anti-cholinesterase 
b. Poor response to IVIG 
c. Good response to immunosuppressive therapy 
d. Good response to therapeutic plasma exchange (TPE) 
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Table 2: TPE procedural data on MuSK MG patients 
 
Table 2A: based on courses 
Parameter Reported 
course number 
Results Courses % 
Plasma volume exchanged 30 1-1.25 total plasma volume 30 100 
Anticoagulant 30 ACD-A 30 100  
Rinse back 30 full 30 100  
Fluid balance 30 100 % 30 100  
Total number of TPE in a course 
 
30 2 2 6.7 
3 5 16.7  
4 3 10.0  
5 14 46.7  
6 2 6.7  
7 2  6.7  
8 1 3.3  
10 1 3.3 
Frequency of TPE  29 every other day 16 55.2  
twice /week  8  27.6  
daily  3  10.3  
weekly  2  6.9  
Access  28 peripheral veins 14 50.0  
central line (IJ) 12 42.9  
central line (SC)  1  3.6  
fistula  1  3.6  
 
TPE: Therapeutic plasma exchange, MuSK: muscle specific kinase, MG: myasthenia gravis, ACD-A: anticoagulant citrate dextrose 
solution A, IJ: internal jugular vein, SC: subclavian vein, 
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Table 2B: Based on procedures 
Parameter Reported  
Procedure number 
Results Procedures % 
Replacement fluid  
 
145 5% albumin only 133 91.7 
5% albumin and normal saline  12  8.3  
Calcium supplementation 
 
136 added into albumin 114  83.8 
oral  1 0.7 
none  21  15.4 
Other supplementation  145 potassium, magnesium 0  0 
RBC priming 145  0  0  
Adverse events  145 5 procedures   3.4 
     citrate toxicities   2  1.4 
     feeling of coldness 1   0.7 
     palpitation and SOB 1  0.7 
     hematoma at needle site 1  0.7 
 
SOB: Shortness of breath 
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Table 3: Percentages of objective symptoms and full recovery of symptoms after a course of TPE  
 Onset (n=15) Before TPE (n=30) Full recovery of symptom 
Diplopia 93.3% (14/15) 40.0% (12/30) 83.3% (10/12) 
Ptosis 40.0% (6/15) 40.0% (12/30) 75.0% (9/12) 
Dysarthria 60.0% (9/15) 66.7% (20/30) 80.0% (16/20) 
Dysphagia 73.3% (11/15) 56.7% (17/30) 94.1% (16/17) 
Weakness 46.7% (7/15) 46.7% (14/30) 92.9% (13/14) 
SOB 40.0% (6/15) 40.0% (12/30) 91.7% (11/12) 
Intubation 13.3% (2/15) 6.7% (2/30) 100.0% (2/2) 
 
Note: At onset, the percentage is based on total number of patients (n=15).  Before TPE, the percentage is based on total number of 
courses (n=30).  For full recovery of symptoms, the percentage is based on the number of course that patient had symptoms before 
TPE (numerator of before TPE in each symptom).    
TPE: Therapeutic plasma exchange, SOB: Shortness of breath 
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Table 4: Subjective improvement after a course of TPE 
 
Patient Course Number of TPE 
in a course 
Final subjective 
 improvement 
1 1 5 Mild 
 2 5 No 
2 3 3 Moderate 
3 4 4 Mild 
4 5 5 Moderate 
5 6 5  
 7 4  
6 8 5 Moderate 
 9 3 Marked 
 10 4 Full 
7 11 5 Marked 
 12 3 Moderate 
 13 7  
 14 6 Mild 
  15 5  
 16 2 Mild 
8 17 5 Full 
 18 3 Full 
9 19 5 Full 
10 20 5  
11 21 5 Marked 
 22 5 Marked 
 23 5 Marked 
12 24 5 Marked 
13 25 10 Marked 
 26 8 Moderate 
 27 7 Mild 
 28 6 No 
14 29 3 Mild 
15 30 2 No 
 
TPE: Therapeutic plasma exchange 
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Table 5: Percentage of subjective improvement after each TPE 
 
 After 1
st
 TPE After 2
nd
 TPE After 3
rd
 TPE After 4
th
 TPE After >5 TPE 
(at the end of course) 
Number of reported courses 25 21 17 15 5 
No improvement 36.0% (9/25) 19.0% (4/21) 5.9 % (1/17) 6.7% (1/15) 20.0% (1/5) 
Mild improvement 40.0% (10/25) 42.9% (9/21) 35.3% (6/17) 20.0% (3/15) 40.0% (2/5) 
Moderate improvement 16.0% (4/25) 28.6% (6/21) 29.4% (5/17) 20.0% (3/15) 20.0% (1/5) 
Marked improvement 8% (2/25) 0% (0/21) 29.4% 5/17) 40.0% (6/15) 20.0% (1/5) 
Full improvement 0% (0/25) 9.5% (2/21) 0% (0/17) 13.3% (2/15) 0% (0/5) 
Any  improvement 64.0% (16/25) 80.1% (17/21) 94.1% (16/17) 93.3% (14/15) 80.0% (4/5) 
 
TPE: Therapeutic plasma exchange 
Note: The occurrence percentage of improvement is based on the number of reported courses in each evaluation time. 
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Table 6: Pre-procedure medications 
 
Medication 30 courses % 
none 6 20.0 
prednisone 17 56.7 
hydrocortisone 1 3.3 
methylprednisone 0 0 
pyridostigmine 13 43.3 
IVIG 3 10.0 
rituximab 1 3.3 
azathioprine 3 10.0 
mycophenolate mofetil 1 3.3 
cyclosporine 0 0 
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Table 7: Change of medication after a course of TPE 
 
7A: Prednisone 
 Right after (14 courses) 3 months after (13 courses) 
Courses % Courses % 
Decreased 1 7.1 4 30.8 
Increased 2 14.3 0 0 
No change 11 78.6 9 69.2 
 
7B: Pyridostigmine 
 Right after (6 courses) 3 months after (5 courses) 
Courses % Courses % 
Decreased 4 66.7 4 80.0 
Increased 0 0 0 0 
No change 2 33.3 1 20.0 
 
TPE: Therapeutic plasma exchange 
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